v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 71,859 $ 72,310
Short-term investments (note 3) 58,000 70,000
Research and development tax credits receivable 816 725
Prepaid expenses 6,292 5,428
Other receivables 277 223
Total current assets 137,244 148,686
Operating lease right-of use asset 914 980
Property and equipment 285 308
Total assets 138,443 149,974
Current liabilities    
Accounts payable and accrued liabilities (note 4) 5,564 5,914
Current portion of operating lease liabilities 252 245
Total current liabilities 5,816 6,159
Operating lease liabilities 635 696
Total liabilities 6,451 6,855
Shareholders’ Equity (note 5)    
Common shares, no par value, unlimited shares authorized 29,846,000 shares issued and outstanding as of March 31, 2021, 29,827,997 shares issued and outstanding as of December 31, 2020 251,716 251,682
Pre-funded warrants - 11,417,034 issued and outstanding as of March 31, 2021 and as of December 31, 2020 48,007 48,007
Additional paid-in capital 9,883 8,530
Cumulative translation adjustment (1,634) (1,634)
Accumulated deficit (175,980) (163,466)
Total shareholders’ equity 131,992 143,119
Total liabilities, and shareholders’ equity $ 138,443 $ 149,974